Levetiracetam Aristo (Levetiracetam)

Levetiracetam works by binding to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates vesicle exocytosis, stabilizing neuronal firing and decreasing abnormal electrical activity that leads to seizures.

The appropriate dose of Levetiracetam Aristo is individualized by the prescribing healthcare professional based on the patient’s age, weight, renal function and seizure type. The prescriber will set the initial dose and any subsequent titration according to clinical response and tolerability.

Levetiracetam is classified as pregnancy category B, indicating that animal studies have not shown risk and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the risk. Limited data suggest it is excreted in breast milk; breastfeeding decisions should be made with a physician.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers or GABA‑enhancers. It has a relatively favorable drug‑interaction profile, does not require routine therapeutic drug monitoring, and is generally well tolerated, making it a common alternative when other agents are ineffective or poorly tolerated.

Store Levetiracetam Aristo tablets at ambient temperature below 25 °C, in the original packaging, protected from moisture and direct light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral formulation.

Levetiracetam Aristo is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water. The exact timing and frequency depend on the individualized dosing schedule set by the treating clinician.

Serious risks include severe psychiatric reactions such as depression, suicidal thoughts or behavior, and rare but potentially life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for mood changes, rash, or any signs of hypersensitivity, and medical attention sought promptly if they occur.

Levetiracetam is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for individuals with severe renal impairment who may require dose adjustment, and for those with a history of serious psychiatric disorders, where alternative therapies might be considered.